देश: आयरलैंड
भाषा: अंग्रेज़ी
स्रोत: HPRA (Health Products Regulatory Authority)
VINORELBINE
Fannin Limited
L01CA04
VINORELBINE
10 Mg/Ml
Concentrate for Soln for Inf
Product subject to prescription which may not be renewed (A)
Vinca alkaloids and analogues
Authorised
2013-01-04
PACKAE LEAFLET: INFORMATION FOR THE USER VINORELBINE “EBEWE” 10 MG/ML – CONCENTRATE FOR SOLUTION FOR INFUSION Each 1 ml concentrate for solution for infusion contains 10mg Vinorelbine (as tartrate) Each 5ml concentrate for solution for infusion contains 50mg Vinorelbine (as tartrate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or nurse. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Vinorelbine is and what it is used for 2. What you need to know before you use Vinorelbine 3. How to use Vinorelbine 4. Possible side effects 5. How to store Vinorelbine 6. Contents of the pack and other information 1. WHAT VINORELBINE IS AND WHAT IT IS USED FOR Vinorelbine belongs to a family of medicines used to treat cancer called the vinca-alkaloid family. It can be used alone but more commonly it is used in combination with other anti-cancer agents. Vinorelbine can also be used in advanced breast cancer and non-small cell lung cancer. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE VINORELBINE YOU WILL NOT BE GIVEN VINORELBINE if you: • are allergic (hypersensitive) to Vinorelbine or any of the other ingredients of Vinorelbine (see section 6 in this leaflet). are under 18 years of age, you have a low white blood cell (neutrophils, leucocyte) count or a severe infection current or recent (within 2 weeks), If you have a low platelet count (thrombocytopenia), If you plan to receive a yellow fever vaccination or have just received one WA पूरा दस्तावेज़ पढ़ें
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vinorelbine Ebewe 10mg/ml concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1ml concentrate for solution for infusion contains 10 mg Vinorelbine (as tartrate) Each 5ml concentrate for solution for infusion contains 50 mg Vinorelbine (as tartrate) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Concentrate for solution for infusion Clear, colourless to pale yellow solution The diluted solution for infusion is a clear, colourless or pale yellow solution pH: 3.0-4.0 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Non-small cell lung cancer Advanced breast cancer 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For intravenous infusion only Vinorelbine ® should be administered under the supervision of a physician with extensive experience in therapy with cytostatics. Strictly intravenous administration after appropriate dilution. Intrathecal administration of Vinorelbine ® may be fatal. Instructions for use and handling: refer to section 6.6. Before application it is extremely important to ensure that the intravenous needle is positioned in the vein. Leakage into surrounding tissue during administration of vinorelbine may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. It is recommended to infuse Vinorelbine ® over 6-10 minutes after dilution in 20 -50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection or in glucose solution for injection 5%. Administration should always be followed with at least 250 ml of an isotonic solution infusion to flush the vein. ADULTS_:_ NON-SMALL CELL LUNG CANCER HEALTH PRODUCTS REGULATORY AUTHORITY ______ पूरा दस्तावेज़ पढ़ें